eli lilly tirzepatide fda approval Lilly's gained in December 2024 for treating moderate-to-severe obstructive sleep apnea in adults with obesity, after Phase III trials showed a 20% average weight loss and a roughly Lilly's Mounjaro receives FDA approval

J.NakaiK

Cilastatin protects against cisplatin-induced nephrotoxicity without compromising its anticancer efficiency in rats

A useful framing from a clinical perspective: NAD+ helps patients feel better faster, while Sermorelin helps them function better overall

The soup recipes (Recipes 22 to 24) and Greek yogurt bowl (Recipe 31) are particularly useful during the adjustment period

The SUMMIT trial demonstrated that tirzepatide significantly reduced the risk of HF hospitalisation or an urgent visit requiring intravenous diuretics

Tirzepatide clinical trials have shown an average weight loss of 20-22% of body weight a clinically meaningful result for patients with obesity or weight-related health conditions